Advance on treatment of mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2009.08.023
- VernacularTitle:套细胞淋巴瘤治疗进展
- Author:
Kaili ZHONG
;
Weijing ZHANG
- Publication Type:Journal Article
- Keywords:
Lymphoma;
mantle-cell;
Therapy;
Antineoplastic combined chemotherapy protocols;
Transplantation
- From:
Journal of Leukemia & Lymphoma
2009;18(8):499-502
- CountryChina
- Language:Chinese
-
Abstract:
Mantle cell lymphoma is an incurable subtype of non-Hodgkin lymphoma. This review focuses on its treatment progress, including high-dose chemotherapy combining rituximab, radioimmunotberapy, autologous stem cell transplatation, allogenetic stem cell transplatation and targeting therapy. Comparing from the disappointed result of regular chemotherapy, adding rituximab or high-dose regimen could improve the effect. And the radioimmunotherapy has also got some potential results. Autologous stem cell transplantation could increase the survival rate, but non-myeloablative allogenetic stem cell transplantation should be considered on relapsed patients. Till now diverse targeted medicine came into clinical trials and some of them seems competent in mantle cell lymphoma.
